Changes in Outpatient Buprenorphine Dispensing During the COVID-19 Pandemic

Jessica Duncan Cance; Erin Doyle

doi:10.1001/jama.2020.22154

Changes in Outpatient Buprenorphine Dispensing During the COVID-19 Pandemic

JAMA. 2020 Dec 15;324(23):2442-2444. doi: 10.1001/jama.2020.22154.

Authors

Jessica Duncan Cance¹, Erin Doyle²

Affiliations

¹ Community Health Research Division, RTI International, Research Triangle Park, North Carolina.
² Texas State Board of Pharmacy, Austin.

Abstract

This study examined outpatient buprenorphine dispensing patterns in Texas before vs after the Drug Enforcement Administration temporarily relaxed outpatient buprenorphine prescribing regulations in March 2020 in response to the COVID-19 pandemic.

MeSH terms

Buprenorphine / therapeutic use*
COVID-19*
Drug Prescriptions / statistics & numerical data*
Drug Utilization / trends
Government Regulation
Humans
Medically Uninsured
Narcotic Antagonists / therapeutic use*
Opioid-Related Disorders / drug therapy*
Pandemics*
Texas

Substances

Narcotic Antagonists
Buprenorphine